D-0029-2026 Class II Ongoing

Recalled by Rising Pharma Holding, Inc. — East Brunswick, NJ

FDA drug recall D-0029-2026 was initiated by Rising Pharma Holding, Inc. on Oct 7, 2025 and is designated Class II. Reason for recall: Product mix up: complaint received that sealed medication bottle contained Carbidopa, Levodopa, and Entacapone film-coated tablets (37.5 mg/150 mg/200 mg) instead of labelled lower strength… The recall status is ongoing. Affected quantity: 2,064 100-count bottles.

Recall details

Product Type
Drugs
Report Date
Oct 22, 2025
Initiation Date
Oct 7, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
2,064 100-count bottles

Product description

Carbidopa, Levodopa, Entacapone Tablets, 25 mg/100 mg/200 mg, 100-count bottle, Rx Only, Manufactured for: Rising Pharma Holdings, Inc. East Brunswick, NJ, 08816, Manufactured by Suven Pharmaceuticals Limited, Pashamylaram, Telangana, 205307, India. NDC# 16571-691-01

Reason for recall

Product mix up: complaint received that sealed medication bottle contained Carbidopa, Levodopa, and Entacapone film-coated tablets (37.5 mg/150 mg/200 mg) instead of labelled lower strength Carbidopa, Levodopa, and Entacapone film-coated tablets (25 mg/100 mg/200 mg).

Distribution pattern

Distributed Nationwide in the USA

Code information

Lot # CS25070, exp. date 03/31/2027

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0029-2026
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0029-2026. Report a data issue: hello@regdatalab.com.